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Introduction
Overweight and obesity is a worldwide problem that impacts 
severely on population health (Newcomer and Haupt, 2006). 
Since the prevalence of overweight and obesity is higher in indi-
viduals with severe mental illnesses than in the general popula-
tion (Elmslie et al., 2000; Holt and Peveler, 2009), their risk of 
harmful consequences is also higher (Hayes et al., 2017; Osborn 
et al., 2007). Individuals with severe mental illnesses are more 
susceptible to developing metabolic syndrome, type-2 diabetes 
mellitus (De Hert et al., 2006) and cardiovascular diseases (Emul 
and Kalelioglu, 2015; Osborn et al., 2007), leading to a higher 
risk of death. Adults with schizophrenia have three and a half 
times the mortality risk than the general population, with cardio-
vascular diseases the most common cause (Olfson et al., 2015; 
Osborn et al., 2007). Particularly, Lahti et al. demonstrated that 
the risk of death is higher in women than in men with schizophre-
nia (Lahti et al., 2012), suggesting that differences between sexes 
need to be further investigated.
Second-generation antipsychotics (AP) are a known cause of 
weight gain (Bak et al., 2014; Osborn et al., 2018). Some evi-
dence suggests that women gain more weight than men during 
AP treatment (Seeman, 2008). One study suggested that women 
have five times the odds of increasing body mass index (BMI) 
compared with men after a period of two years or more (Koga, 
2003). Of women treated with clozapine, 29% gained ⩾ 20% of 
their baseline body weight after two years of follow up, in con-
trast to 13% of men (Covell et al., 2004). Other studies have dem-
onstrated similar differences between men and women (Gebhardt 
et al., 2009; Najar et al., 2017). However, most of these studies 
are based on small sample sizes of less than 200 individuals, and 
most do not distinguish between short- and long-term weight 
gain associated with antipsychotic treatment.
Weight gain after initiation of antipsychotic treatment may 
also depend on body weight when treatment is initiated. Thus, 
Gebhardt et al. found that low BMI before first AP treatment 
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predicted a faster increment of BMI after treatment initiation 
(Gebhardt et al., 2009), and a similar conclusion was reached by 
Najar et al. (2017). On the other hand, we have limited informa-
tion about how doses of antipsychotic treatment are associated 
with weight gain (Bak et al., 2014).
In this study, our aim was to investigate the change in body 
weight of patients initiated with high or low doses of the three most 
commonly prescribed second-generation antipsychotics: olanzap-
ine, risperidone and quetiapine. Our objectives were to evaluate:
(1) the short- and long-term change in body weight in men 
and women upon initiation of AP;
(2)  whether this is different for low and high doses;
(3) whether low body weight at treatment initiation had the 
greatest weight gain.
Methods
Data source
We used anonymized, longitudinal patients’ records from The 
Health Improvement Network (THIN), a database that comprises 
information from UK primary care electronic health records from 
general practices (Roland et al., 2012). THIN integrates more 
than 12 million patients from 711 general practices, including 
demographic data (sex, year of birth and indicator of social dep-
rivation (quintiles of Townsend score)) and clinical data. The 
clinical data are recorded using the hierarchical Read Code sys-
tem (Chisholm, 1990). In the UK, more than 95% are registered 
with a general practice, THIN is roughly representative of the UK 
population and has been previously used for reporting health 
indicators at the national level (Blak et al., 2011). For this study, 
we included data from all practices after they have been deemed 
to be operating at the standard of acceptable computer usage 
(Horsfall et al., 2013) and whose reported mortality rate was con-
sistent with national statistics (Maguire et al., 2009).
Study population
At the individual level, we included all patients aged between 18 
and 99 years at the date they started their first treatment with olan-
zapine, risperidone or quetiapine; between 1 January 2005 and 31 
December 2015. We included patients with a diagnosed psychiat-
ric disorder (schizophrenia, bipolar disorder, other non-affective 
psychoses, borderline personality disorder, anxiety, depression or 
dementia) who had at least one further prescription of the same 
AP within three months after the first prescription. We judged that 
these individuals were more likely to have initiated treatment than 
those with a single prescription. Patients who had been initiated 
on more than one type of AP were excluded (including switchers). 
A few individuals had no records of year of birth, sex or social 
deprivation records and were thus excluded from our study. 
Likewise, we excluded individuals with no available data 
12 months before the date of initiation of antipsychotic treatments 
since they may have initiated antipsychotic treatment elsewhere.
Variables and measurements
The exposure of interest was the initiation of olanzapine, risperi-
done or quetiapine prescription. In the Neuroscience-based 
Nomenclature olanzapine is a dopamine and serotonin receptor 
antagonist, risperidone is a dopamine, serotonin and norepineph-
rine receptor antagonist, and quetiapine is a dopamine and sero-
tonin receptor antagonist and norepinephrine reuptake inhibitor 
(Nutt and Blier, 2016). The outcome was body weight, measured 
in kilograms. The main covariates were sex (women/men) and 
first prescribed dose of AP (hereafter called ‘first dose’). All AP 
reported first doses in milligrams, but we used the dose-equiva-
lence approach of Woods (Woods, 2003) for defining cut-off 
points of low/high first dose: ⩽ 5 mg for olanzapine, ⩽ 75 mg for 
quetiapine and ⩽ 2 mg for risperidone. Using the ‘2 mg of halop-
eridol equals 100 mg of chlorpromazine’ convention as reference, 
Woods (2003) explored available evidence for identifying the 
minimum effective dose across olanzapine, quetiapine and risp-
eridone, defining this dose equivalence. The first dose is a good 
predictor of all subsequent doses prescribed during treatment; 
thus, over time, patients usually stay in a dose range close to 
the first dose they were prescribed (data not shown). We also 
retrieved information on age, height, social deprivation 
(Townsend score 1–5, from least to most deprived), smoking and 
drinking status, having a type-2 diabetes mellitus diagnosis, sys-
tolic blood pressure (SBP), low-density lipoprotein cholesterol 
(LDL-cholesterol) and high-density lipoprotein cholesterol 
(HDL-cholesterol); recorded within first year of initiation of 
treatment. This information served mostly for sample characteri-
zation; only sex, age, type-2 diabetes mellitus diagnosis and 
social deprivation were fully observed.
Statistical analysis
We used an interrupted time series approach (Bernal et al., 2017) 
to analyse weight change over time, with one model for each of 
the three AP initiation cohorts by sex (six models in total, one per 
drug per sex). We modelled weight change over time using con-
tinuous linear splines with random intercept and slopes models 
(unstructured covariance, restricted maximum likelihood), from 
which three slopes of weight change were estimated for: (a) 
–4 years to baseline (pre-treatment), (b) baseline to +6 weeks 
(short-term), (c) +6 weeks to +4 years (long-term). Differences 
between slopes served to describe weight change after AP treat-
ment initiation, both crude and adjusted for age and social depri-
vation (objective 1). The correlation between average weight at 
baseline (intercept) and short-term gradient of change (short-
term slope) was estimated, as it provided an estimate for whether 
individuals with lower weight at baseline gain more or less 
weight after AP treatment initiation than individuals with higher 
body weight. Negative correlations mean that individuals with 
low weight gain more weight during the short-term period and 
vice versa (objective 3). Our main analysis was performed after 
stratifying each of cohorts according to low/high first dose. This 
was to examine whether the gradient of weight change after treat-
ment varies between low/high first doses of AP (objective 2). For 
all these models, the Intraclass Correlation Coefficient (ICC) was 
reported. Likelihood ratio tests were performed to compare the 
goodness of fit between the nested models. We assumed weight 
records were missing at random within strata, conditional on 
observed weights, so that modelling the observed data over time 
provides unbiased estimates (van Buuren, 2012). We also 
assumed missing data on dose was missing at random, so that the 
complete case analysis we performed provides unbiased esti-
mates (White and Carlin, 2010). Model assessment included 
evaluation of residuals and a visual exploration of average and 
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individual trajectories. Although the chosen impact model (linear 
splines with knots at baseline and +6 weeks) was informed by 
both the clinical criteria and evidence (Bak et al., 2014), we also 
performed a sensitivity analysis following the suggestions from 
Lopez Bernal et al. (Bernal et al., 2017). This sensitivity analysis 
consisted of comparing our preferred linear spline model against 
another feasible impact model, a restricted cubic spline model 
(knots again at baseline and +6 weeks), using graphical and ana-
lytical tools (see Figure S1 in supplemental material). Estimates 
are given with 95% confidence intervals (CIs). All the statistical 
analyses were performed using Stata 15 for Windows (Stata, 
2017).
Results
In total, we included 16,559 men and 22,306 women in the study. 
The median number ± interquartile range of weight measure-
ments within individual trajectories over eight years of observa-
tion were 6 ± 7 and 8 ± 10 (olanzapine cohorts), and 7 ± 8 and 
8 ± 9 (quetiapine and risperidone cohorts) for men and women 
respectively. Characteristics of the individuals are summarized in 
Figure 1 and are provided in more detail in Table S1. On average, 
at initiation of treatment, men were younger than women pre-
scribed olanzapine (men = 47.5 years ±17.8 SD, 
women = 54.0 years ±19.5 SD) and risperidone (men = 56.6 years 
±22.1 SD, women = 64.5 years ±21.8 SD), but were of similar 
age in the quetiapine cohort (men = 56.5 years ±20.7 SD, 
women = 56.1 years ±22.1 SD). On average, men were pre-
scribed higher dose of olanzapine (+1 mg), quetiapine (+10 mg) 
and risperidone (+0.3 mg).
In the short (< 6 weeks) and long term (⩾ 6 weeks to 
⩽ 4 years), individuals treated with any of the three AP drugs 
gained weight, especially those patients prescribed olanzapine. 
Pre-treatment weight change was negligible for quetiapine 
(women and men) and risperidone (men only) cohorts, and 
slightly negative for the rest of cohorts. In the short-term after 
olanzapine initiation, men’s weight increased by 0.569 kg/week 
(3.4 kg over the first six weeks) and women’s weight increased 
by 0.382 kg/week (2.3 kg over the first six weeks) (Tables 1 and 
S2). Individuals initiated on quetiapine and risperidone also 
gained weight shortly after initiation of treatment, but to a lesser 
extent (Tables 1 and S2, and Figure 2). Individuals continued to 
gain weight after six weeks, but at a slower rate than the first six 
weeks. For example, for women initiated on olanzapine, long-
term weight gain was estimated to be 0.014 kg/week (0.7 kg per 
year) (Tables 1 and S2, and Figure 2). Women who were initiated 
on olanzapine were in general slightly lighter (69.7 kg) than 
women initiated on risperidone (73.3 kg) and quetiapine (70.1 kg), 
but there was not much difference for the men (weight at base-
line, see Figure 1 and Table S2). Women who had a lower weight 
before initiation of olanzapine gained more weight in the short 
term than women who had a higher weight (correlation between 
intercept and slope = –0.068, 95% CI: –0.121 to −0.014); a simi-
lar effect was observed for men (correlation between intercept 
and slope = –0.050, 95% CI: –0.113 to +0.014) (Table S2).
The weight gain in individuals who were initiated on high 
dose of AP was greater than those initiated on low dose. When 
olanzapine was initiated at high dose (> 5 mg), women gained 
+0.534 kg/week (+3.2 kg over 6 weeks) and men +0.743 kg/
week (+4.5 kg over 6 weeks) compared with low-dose gain of 
+0.314 kg/week (+1.9 kg over 6 weeks) for women and 
+0.425 kg/week (+2.6 kg over 6 weeks) for men (Tables 1 and 
S3). The short-term effect of initiation of quetiapine was also 
stronger for those given high doses (> 75 mg) (women +2.3 kg 
and men +1.6 kg, both over 6 weeks) than given low doses 
(women +0.7 kg and men +0.5 kg, both over 6 weeks). However, 
there was a relatively small difference for those initiated on risp-
eridone low doses (⩽ 2 mg) (+1.0 kg over 6 weeks for both 
women and men) and high doses (women +1.1 kg and men 
1.9 kg, both over 6 weeks). In the short-term, those given low 
doses of olanzapine tended to gain more weight as their weight at 
baseline was lower (women: correlation between intercept and 
slope = –0.155, 95% CI: –0.230 to −0.078; men: correlation 
between intercept and slope = –0.135, 95% CI: –0.235 to −0.033).
Cumulative weight gain in the long-term was particularly 
high in patients prescribed olanzapine but, for any drug, people 
did not on average lose the extra-weight they gained during the 
short-term (Table 1 and S3). For example, after four years from 
the first olanzapine prescription, a typical woman gained 2.3 kg 
(short-term, 95% CI: 1.9–2.7 kg) + 2.8 kg (long-term, 95% CI: 
2.2–3.5 kg)  = 5.1 kg (total) whereas a typical man gained 3.4 kg 
(short-term, 95%CI: 3.0–3.8 kg) + 1.7 kg (long-term, 95% CI: 
0.9–2.4 kg) = 5.1 kg (total) of AP induced extra-weight. The pre-
scribed dose of olanzapine was also critical, particularly for 
women in the long-term. For example, given a low dose (< 5 mg), 
women gained 1.9 + 2.5 = 4.4 kg after four years; given a high 
dose (> 5 mg), women gained 3.2 + 2.9 = 6.1 kg. A similar impact 
of higher doses was observed for quetiapine and risperidone 
(Table 1 and S3).
Discussion
This retrospective cohort study reports data from patients seen in 
primary care, before and after AP treatment initiation. Pre-
treatment weight change was insignificant or slightly negative 
for all cohorts during four years before baseline. Individuals 
starting treatment with any AP gained weight on average, espe-
cially those patients prescribed olanzapine. Weight gain was 
much more rapid in the short-term than in the long-term. People 
who were initiated on high-dose AP experienced much greater 
absolute weight gain than those initiated on low dose AP. 
Cumulative weight gain during the long-term was particularly 
high in individuals treated with olanzapine but, for all APs, peo-
ple typically never lost the extra weight they gained during the 
first six weeks of AP treatment.
Strengths and limitations of this study
This study presents evidence from a large sample (n > 38,000) of 
people prescribed antipsychotic medications, taken from a popu-
lation which is broadly representative of the UK (Blak et al., 
2011). Patients prescribed antipsychotics are often treated for 
long periods, and so quantifying the risk of long-term side effects 
is particularly important. Clinical trials invariably fail to do this 
because of their short durations and much smaller sample size, so 
our study provides a necessary long-term perspective. We applied 
an analysis approach that has not been used previously in assess-
ing AP-induced weight gain. A major advantage of our approach 
is that it includes pre-treatment weight change information, so 
4 Journal of Psychopharmacology 00(0)
patients act as their own controls in the analysis and any addi-
tional weight change after baseline is attributable to the AP treat-
ment. The approach utilizes all individual weight records at their 
time of measurement, therefore avoiding the loss of information 
seen in previous studies which categorize outcomes or use period 
means or incidence rates as summary measures (Bak et al., 2014; 
Osborn et al., 2018). Our longitudinal model-based approach also 
accounts for missing weight records – assuming weight record-
ing is missing at random within strata, conditional on observed 
weight measurements (Haneuse et al., 2016) – while incorporat-
ing informative pre-baseline weight data. From this method we 
expect unbiased estimates if data were missing at random 
(Molenberghs et al., 2014), a property that is not ensured by com-
plete case analyses applied elsewhere (Bushe et al., 2012; Osborn 
et al., 2018). Following standard recommendations (Bernal et al., 
2017), we guaranteed good statistical power by having equal 
periods of observation before and after baseline, and a large sam-
ple size. Additional analyses showed that our proposed linear 
Figure 1. Baseline characteristics of patients from olanzapine, quetiapine and risperidone cohorts, stratified by sex. From height onwards, some 
continuous variables changed their scale as labelled below their names.
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spline models were very similar to the restricted cubic splines 
models (Figure S1), and for primary analysis we used the former 
as interpretation is more straightforward.
Our study does have a number of potential limitations. 
Information on possible time-varying confounders (for example, 
symptoms level or illness severity) was not included, however, it 
Table 1. Expected weight gain for an average patient prescribed a particular antipsychotic, stratified by dose and sex.
Drug Sex na Doseb Weight gained during 
short-time (0–6 weeks), kg
95% CI Weight gained during long-
time (6 weeks–4 years), kg
95% CI Total weight 
gained
OLANZAPINE 
(n = 9499)
Women 5004 Overall 2.3 (1.9–2.7) 2.8 (2.2–3.5) 5.1
2535 Low 1.9 (1.4–2.4) 2.5 (1.6–3.3) 4.4
1100 High 3.2 (2.4–4.0) 2.9 (1.6–4.2) 6.1
Men 4495 Overall 3.4 (3.0–3.8) 1.7 (0.9–2.4) 5.1
1887 Low 2.6 (2.0–3.2) 1.9 (0.8–3.0) 4.5
1470 High 4.5 (3.6–5.3) 1.4 (0.2–2.7) 5.9
QUETIAPINE 
(n = 19,965)
Women 12,149 Overall 1.2 (1.0–1.5) 1.1 (0.6–1.6) 2.3
5372 Low 0.7 (0.3–1.0) 0.9 (0.1–1.6) 1.6
1912 High 2.3 (1.6–2.9) 1.6 (0.4–2.7) 3.9
Men 7816 Overall 0.8 (0.4–1.1) 0.7 (0.1–1.3) 1.5
3326 Low 0.5 (0.0–0.9) −0.7 (–1.8–0.3) −0.3
1326 High 1.6 (0.9–2.4) 1.0 (–0.3–2.2) 2.6
RISPERIDONE 
(n = 9401)
Women 5153 Overall 0.9 (0.5–1.3) 0.7 (–0.1–1.5) 1.6
3102 Low 1.0 (0.5–1.4) 0.1 (–0.9–1.1) 1.1
316 High 1.1 (–0.7–2.9) 3.5 (1.0–5.9) 4.6
Men 4248 Overall 1.1 (0.6–1.5) 1.4 (0.4–2.4) 2.5
2411 Low 1.0 (0.4–1.7) 1.1 (–0.3–2.6) 2.2
441 High 1.9 (0.5–3.3) 1.4 (–0.7–3.5) 3.3
aOverall estimates come from Table S2 (n = 38,865) and low/high dose estimates come from Table S3 (n = 25,198). n from Table S2 < n from Table S3 due to missing data 
on dose.
bCut off point for low/high dose was: ⩽ 5 mg for Olanzapine, ⩽ 75 mg for Quetiapine and ⩽ 2 mg for Risperidone.
Figure 2. Changes in body weight over time before and after treatment initiation by drugs and sex.
6 Journal of Psychopharmacology 00(0)
is reasonable to assume limited variation from patients’ baseline 
values for unmeasured confounders. Treatment initiation has 
been defined using first prescription date in general practice; but, 
for some individuals, the first prescription date might occur while 
the individual is under the care of secondary care mental services 
(these data are not recorded in primary care). However, it is most 
likely these patients have a first prescription date very close to 
the one in primary care, thus no major impact on estimates is 
expected.
We did not control for drugs prescribed to reduce antipsy-
chotic-induced weight gain, or for multiple prescriptions of other 
drugs that could potentially affect weight as well. However, we 
know that drugs prescribed for ameliorating weight gain would 
only reduce the estimate of the real weight gain of the target pop-
ulation, thus we are not overestimating the weight gain effect. We 
did not assess weight gain associated with other antipsychotic 
medications as there were not enough data on them, but the three 
drugs included in this study are the most commonly prescribed 
antipsychotic medications in the UK (Marston et al., 2014) and 
have previously been associated with weight gain (Osborn et al., 
2018). The weight gain trajectories we described are averages, 
thus they should be interpreted as typical patient trajectories. In 
practice, individual patients’ weight gain will vary from these 
average trajectories. However, the first weeks of treatment are 
critical for everyone. Finally, we did not control the number of 
prescriptions beyond the second prescription (treatment dura-
tion), meaning that studied patients can include those treated for 
long periods, those treated sporadically, just for a short period, or 
those who did not adhere to treatment regularly. This lack of con-
trol may reduce our long-term estimates of weight gain, but, 
given the evidence about dosage, we anticipate that patients 
exposed to AP on a regular basis and for long periods will have 
larger estimates of long-term weight gain.
Comparison with other studies
Previous studies have suggested olanzapine is associated with a 
large short-term weight gain whereas risperidone and quetiapine 
have a moderate effect on weight (Bak et al., 2014). In the long-
term, contrary to one previous finding (Haddad, 2005), we found 
that weight gain did not stabilize during four years of follow up. 
However, our finding of long-term effect of weight gain is con-
sistent with previous studies by Bushe et al. (2012) and Osborn 
et al. (2018), but we are able to quantify the effect more accu-
rately. Previous research has suggested women’s weight is more 
affected by AP exposure (Seeman, 2008); however, we found that 
only olanzapine (in the long-term) and quetiapine (in the long 
and short-term) induced more weight gain in women. Since our 
study population is a mixture of naïve and recurrent antipsychotic 
consumers, short- and long-term weight gain in olanzapine naïve 
individuals and long-term weight gain in risperidone naïve indi-
viduals can be higher than the weight gain reported by us (Bak 
et al., 2014). Risperidone seemed to be associated with greater 
weight gain in men than women both in the short- and long-term, 
and men prescribed olanzapine gained more weight in the short-
term. Regarding the dosage, one recent study reanalysed results 
of 14 clinical trials to explore variations in weight gain across 
doses of olanzapine and risperidone (Spertus et al., 2018). Their 
conclusions about olanzapine are consistent with our results; that 
the excess risk of at least 7% weight gain is 16.1% for low doses 
(0–10 g chlorpromazine equivalent dose) and 46.8% for high 
doses (0–20 g chlorpromazine equivalent dose). They could not 
be conclusive about the effects of risperidone as they showed 
only a trend in weight gain; however, this trend is in line with our 
findings. Some advantages from our original study are: (a) we 
added similar information about quetiapine, (b) we observed 
longer periods of weight change (four years) and (c) we analysed 
information at individual-level from cohorts with more than 
38,000 patients in total.
Conclusions and policy implications
Over a four-year period, olanzapine treatment was associated with 
the highest increase in weight with around 6 kg for those on high 
dose and 4.5 kg for those on low dose. The weight gain was less 
dramatic for individuals treated with quetiapine and risperidone. 
In general, individuals did not lose the weight gained during the 
first six weeks of treatment. Doctors and patients may want to take 
the issue of a substantial weight gain into consideration when 
making decisions on initiation of antipsychotic treatments, and 
doctors should prescribe the lowest effective dose to balance men-
tal health benefits, weight gain and other adverse effects.
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